Amylyx is a pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases.
AMLX
25.18 as of 6/2/23
| Date | Funding Round | Funding Raised | Price per Share | IPO Valuation |
|---|---|---|---|---|
| 7/20/2021 | Series C-1 and C-2 | $135MM raised | $XXX.XX | $XXX.XX |
| 7/1/2020 | Series B | $60.52MM raised | $XXX.XX | $XXX.XX |
| 8/23/2016 | Series A | $7.73MM raised | $XXX.XX | $XXX.XX |
